b'B:16.25"T:15.75"S:15.25"Now ACIP-RecommendedThe CDCs ACIP recommends ABRYSVO TMfor adults 60 years and older 1,2Adults 60 years and older may receive a single dose of ABRYSVO using shared clinical decision making. This recommendation hasLearn how ABRYSVObeen ocially adopted by the CDC Director and was published incan help protect yourDISCOVER THE DATAthe MMWR on July 21, 2023. 1,2 older adult patientsat SeeABRYSVO.comthis RSV season 1 S:10.25" T:10.75" B:11"ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; MMWR=Morbidity and Mortality Weekly Report; RSV=respiratory syncytial virus. References: 1. ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. P zer Inc; May 2023. 2. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization PracticesUnited States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801.INDICATIONABRYSVO is a vaccine indicated for active immunization for the prevention of lower Vaccination with ABRYSVO may not protect all vaccine recipientsrespiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in In clinical trials, the most commonly reported (10%) adverse reactions were individuals 60 years of age and older. fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%) IMPORTANT SAFETY INFORMATIONPlease see Brief Summary of full Prescribing Information for ABRYSVO on theDo not administer ABRYSVO to individuals with a history of a severe allergic reactionfollowing pages.(e.g., anaphylaxis) to any component of ABRYSVOAppropriate medical treatment must be available in case of an anaphylactic reactionSyncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from faintingImmunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO PP-A1G-USA-00292023 P zer Inc. All rights reserved. August 2023FS:7.25" FS:7.25"F:7.875" F:7.875"12059297_US OA HCP_US Med Jrnl_Ad Update_M2FR.indd 1 PREPARED BY 12/1/23 6:40 PM12059297_vc#12009360 US OA HCP US Med Jrnl Ad Update M2FRJob info Images FontsSpecial InstructionsDate: 12-1-2023 6:40 PM ABRYSVO_Gradient_CMYK_no text.ai (60.1%,Roboto (Regular, Italic, Bold, Medium), Comfor- Release files to Emily.Phelan@fcbhealth.com, Client: Pfizer 23.71%; 1.6MB), PFIZ_A093449_4C.psd (CMYK;taa (Bold) Emily.Carter@mccannhealth.comProduct: ABRYSVO-Older Adult 299 ppi; 100.01%; 66.4MB), SWOOSH_CMYK_Client Code: None Flat.ai (47.96%, 46.49%; 176KB), ABRYSVO_ Additional InformationWF Issue # 9989474 Lockup_CMYK_Full_Color_5.8.2023.ai (18%;NoneReleasing as: PDFx1A 1.1MB), Pfizer_Logo_4C_CMYK.eps (5.4%, Final Size: 15.75"w x 10.75"h 5.48%; 2.6MB), QR Code31545-246880054 Finishing: None (77.82%; 28KB)Gutter: .375" Inks Additional Comments for SizingColors: 4cCyan, Magenta, Yellow, Black NoneTeamProducer: Emily PhelanAD: N/AAE: Emily Carter Scale: 1"= 1"QC: None Bleed 16.25" w x 11" h16.25" w x 11" hProduction: Laura G Trim/Flat 15.75" w x 10.75" h15.75" w x 10.75" hDigital Artist: M. Tenga Live/Safety 15.25" w x 10.25" h15.25" w x 10.25" h Path: PrePress:Pfizer:ABRYSVO:12059297:_Packaged_Jobs:12059297_US OA HCP_U.d Jrnl_Ad Update_M2FR:12059297_US OA HCP_US Med Jrnl_Ad Update_M2FR.inddPDFX1A _'